The fourth Journal Club
-
9 February 2026 | 2:30 PM
-
Online
About the Event
The following manuscript will be discussed:
The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells.
It is a recent publication that investigates the mechanisms of action of empagliflozin, a medication used in clinics with beneficial effects on the heart. Authors examined effects of empagliflozin on the metabolism of glucose and fatty acids in models of skeletal muscle cells.
Organized by the VRC Cardiovascular Research.
Additional Information
| Accessibility | Without specific accessibility measures |
|---|